Cosdosiran

N/A

Report date: 2023/01/31 10:06:37
NME

Base Information

Drug NameCosdosiran
Drug Alias NamesiCASP2QPI-1007RBD-1007SR061
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionGene expression inhibitorsRNA interferenceCaspase-2 inhibitors
TargetsCaspase-2
Therapy Area/IndicationsGlaucoma, Angle-ClosureGlaucomaOptic Neuropathy, Ischemic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesVietnamSingapore +[9] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesBiospringQuark Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiocon LtdSuzhou Ribo Life Science Co Ltd
Inactive CompaniesQuark Pharmaceuticals IncPyramid Laboratories IncFountain Medical (Tianjin) Co Ltd
Active IndicationsGlaucomaOptic Neuropathy, Ischemic
Inactive IndicationsGlaucoma, Angle-ClosureOptic Atrophy

Other Information

ATC CodeN/A
Related LinksN/A